83 related articles for article (PubMed ID: 8961802)
21. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
Wong JY; Thomas GE; Yamauchi D; Williams LE; Odom-Maryon TL; Liu A; Esteban JM; Neumaier M; Dresse S; Wu AM; Primus FJ; Shively JE; Raubitschek AA
J Nucl Med; 1997 Dec; 38(12):1951-9. PubMed ID: 9430476
[TBL] [Abstract][Full Text] [Related]
22. A distributed pharmacokinetic model of two-step imaging and treatment protocols: application to streptavidin-conjugated monoclonal antibodies and radiolabeled biotin.
van Osdol WW; Sung C; Dedrick RL; Weinstein JN
J Nucl Med; 1993 Sep; 34(9):1552-64. PubMed ID: 8355076
[TBL] [Abstract][Full Text] [Related]
23. Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity.
Elgqvist J; Andersson H; Bäck T; Claesson I; Hultborn R; Jensen H; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
Nucl Med Biol; 2006 Nov; 33(8):1065-72. PubMed ID: 17127181
[TBL] [Abstract][Full Text] [Related]
24. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
25. Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in a breast carcinoma xenograft model.
Tahtis K; Lee FT; Smyth FE; Power BE; Renner C; Brechbiel MW; Old LJ; Hudson PJ; Scott AM
Clin Cancer Res; 2001 Apr; 7(4):1061-72. PubMed ID: 11309358
[TBL] [Abstract][Full Text] [Related]
26. Targeting strategies for cancer radiotherapy.
Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
[TBL] [Abstract][Full Text] [Related]
27. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
28. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
Casey JL; Pedley RB; King DJ; Green AJ; Yarranton GT; Begent RH
Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
[TBL] [Abstract][Full Text] [Related]
29. Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin.
Breitz HB; Weiden PL; Beaumier PL; Axworthy DB; Seiler C; Su FM; Graves S; Bryan K; Reno JM
J Nucl Med; 2000 Jan; 41(1):131-40. PubMed ID: 10647616
[TBL] [Abstract][Full Text] [Related]
30. A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies.
Lin Y; Pagel JM; Axworthy D; Pantelias A; Hedin N; Press OW
Cancer Res; 2006 Apr; 66(7):3884-92. PubMed ID: 16585217
[TBL] [Abstract][Full Text] [Related]
31. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.
Behr TM; Sgouros G; Stabin MG; Béhé M; Angerstein C; Blumenthal RD; Apostolidis C; Molinet R; Sharkey RM; Koch L; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3031s-3043s. PubMed ID: 10541340
[TBL] [Abstract][Full Text] [Related]
32. Designer genes: recombinant antibody fragments for biological imaging.
Wu AM; Yazaki PJ
Q J Nucl Med; 2000 Sep; 44(3):268-83. PubMed ID: 11105590
[TBL] [Abstract][Full Text] [Related]
33. [Application of biotin-avidin system in targeted magnetic resonance imaging].
Liu X; Xu YK; Ye J
Di Yi Jun Yi Da Xue Xue Bao; 2004 Oct; 24(10):1130-2. PubMed ID: 15485783
[TBL] [Abstract][Full Text] [Related]
34. Biochemical modification of streptavidin and avidin: in vitro and in vivo analysis.
Rosebrough SF; Hartley DF
J Nucl Med; 1996 Aug; 37(8):1380-4. PubMed ID: 8708779
[TBL] [Abstract][Full Text] [Related]
35. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy.
Goldenberg DM; Sharkey RM; Paganelli G; Barbet J; Chatal JF
J Clin Oncol; 2006 Feb; 24(5):823-34. PubMed ID: 16380412
[TBL] [Abstract][Full Text] [Related]
36. Radioimmunotherapy in advanced ovarian cancer: is there a role for pre-targeting with (90)Y-biotin?
Grana C; Bartolomei M; Handkiewicz D; Rocca P; Bodei L; Colombo N; Chinol M; Mangioni C; Malavasi F; Paganelli G
Gynecol Oncol; 2004 Jun; 93(3):691-8. PubMed ID: 15196866
[TBL] [Abstract][Full Text] [Related]
37. Enhancement of tumor-to-nontumor localization ratios by hepatocyte-directed blood clearance of antibodies labeled with certain residualizing radiolabels.
Patel S; Stein R; Ong GL; Goldenberg DM; Mattes MJ
J Nucl Med; 1999 Aug; 40(8):1392-401. PubMed ID: 10450693
[TBL] [Abstract][Full Text] [Related]
38. Synthesis, pharmacokinetics, and biodistribution of 67GA deferoxamineacetyl-cysteinylbiotin.
Hashmi M; Rosebrough SF
Drug Metab Dispos; 1995 Dec; 23(12):1362-7. PubMed ID: 8689944
[TBL] [Abstract][Full Text] [Related]
39. Galactose-modified streptavidin-GC4 antifibrin monoclonal antibody conjugates: application for two-step thrombus/embolus imaging.
Rosebrough SF; Hashmi M
J Pharmacol Exp Ther; 1996 Feb; 276(2):770-5. PubMed ID: 8632349
[TBL] [Abstract][Full Text] [Related]
40. A ticket to ride: peptide radiopharmaceuticals.
Fischman AJ; Babich JW; Strauss HW
J Nucl Med; 1993 Dec; 34(12):2253-63. PubMed ID: 8254420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
